Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility StudyLaetitia E. Lamberts, Gooitzen M. van Dam, Maximillian Koch et al.|Clinical Cancer Research|2016Cited by 289
PET imaging of oestrogen receptors in patients with breast cancerMichel van Kruchten, Geke A.P. Hospers, Elisabeth G.E. de Vries et al.|The Lancet Oncology|2013Cited by 206
PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical DilemmaMichel van Kruchten, Geke A.P. Hospers, Andor W.J.M. Glaudemans et al.|Journal of Nuclear Medicine|2012Cited by 166
Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast CancerMaximilian Koch, Vasilis Ntziachristos, P. Beatriz García-Allende et al.|Cancer Research|2016Cited by 43
Data from Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast CancerMaximilian Koch, Vasilis Ntziachristos, Johannes S. de Jong et al.|Unknown|2023Cited by 0